Recent Updates
Recently added Catalysts
VNRX Positive Sentiment

Differentiation of Malignant and Benign Lung Nodules using Epigenetically Modified Nucleosomes in Plasma

Wednesday, October 25, 2023 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: The presentation titled 'Differentiation of Malignant and Benign Lung Nodules using Epigenetically Modified Nucleosomes in Plasma' was delivered by Dr. Pei-Hsing Chen at ESMO 2023. It discusses a novel approach to enhance the diagnosis of lung nodules, potentially improving patient outcomes. The research emphasizes the use of epigenetically modified nucleosomes in plasma for better differentiation.
Price reaction · baseline $16.65 (2023-10-25T16:25:00.000Z) · hit during market hours · 1 other VNRX headline(s) in the window, move may be shared
day 0 close · peak
-2.6%

Market Sentiment Analysis

POSITIVE FACTORS

  • Presentation highlights innovative methods for cancer diagnosis.
  • Potential for improved differentiation between malignant and benign nodules.
  • Research presented at a reputable conference (ESMO 2023).

Full Press Release Details

Presentation title: “Differentiation of Malignant and Benign Lung Nodules using Epigenetically Modified Nucleosomes in Plasma.”
Presented at ESMO 2023
Pei-Hsing Chen, MD

Related Articles

• Press Releases Data Showing the Prognostic Value of its Nu.Q® Cancer Test
• Poster & Publications Cytokine-induced chromatin accessibility in whole blood neutrophils links to sepsis transcriptional states

Data Showing the Prognostic Value of its Nu.Q® Cancer Test

Cytokine-induced chromatin accessibility in whole blood neutrophils links to sepsis transcriptional states

• Share
• Tweet
• Share on Facebook
• Share

Subscribe for Volition product updates .

Or, click here for Investor Updates and press releases .

" * " indicates required fields

Frequently Asked Questions

What was the presentation about?

The presentation focused on differentiating malignant and benign lung nodules using epigenetically modified nucleosomes.

Who presented the research?

The research was presented by Dr. Pei-Hsing Chen at ESMO 2023.

What is the significance of the research?

It highlights a novel approach that could improve the diagnosis of lung nodules.

Where was the research presented?

The research was presented at the ESMO 2023 conference.

ShareAdd on Google
Tags: VNRX Viatris Investor Conferences Healthcare lung cancer ESMO 2023 epigenetics nucleosomes
Last updated: Oct 25, 2023

Biotech snapshot

Cash runway
$3M liquidity · $2M/mo burn
~1 mo
High dilution risk